Publication Year

Nordyke RJ, Cyr P, Jensen I. Gene therapy development programs are both growing and evolving in the face of commercial headwinds. Poster Session 3/No. HPR71, ISPOR 2026, Philadelphia, PA, May 19, 2026.

Nordyke RJ, Jensen I, Hooda N, Miller B. Rising levels of innovation in expedited designations among FDA-approved drugs: 2012-2024. Poster Session 2/No. HPR63, ISPOR 2026, Philadelphia, PA, May 18, 2026.

Fitch S, Lozy F, Mitchell C, Patlewicz G, Wood A. Use of new approach methodologies in the safety assessment of dietary supplements—Parts one and two. Webinar series, Council for Responsible Nutrition (CRN), Washington, DC, May 2026.

Thompson CM, Heintz MM, Rogers SI, Vincent MJ, Haws LC. 2026. Integration of mechanistic and repeat dose toxicity data in the derivation of an oral reference dose for HFPO-DA. Toxicol Sci 209(5):kfag045; doi: 10.1093/toxsci/kfag045. PMID: 41968070.

Buerger AN, Heintz MM, Haws LC, Thompson CM. 2026. Mode-of-action and human relevance assessment for diisononyl phthalate-induced liver tumors in rodents. J Appl Toxicol; doi: 10.1002/jat.70223. Online ahead of print May 5th. PMID: 42086044. 

Pimenta K, Edwards J, Ray M, Naser AM, Price C, Idassi O, Strong K, Were W, et al. 2026. Contemporary global burden of sickle cell anaemia under-5 and under-20: A systematic review and meta-analysis. Br J Haematol 10.1111/bjh.70501. Online ahead of print May 3; doi: 10.1111/bjh.70501. PMID: 42070793.

Doepker C, Franzen A, Brorby G, Brown L, Choksi N, East A, Wikoff D. 2026. Smoke flavoring—A case study demonstrating the value of using benefit-risk analysis for foods (BRAFO) to provide transparency for risk management decisions. Regul Toxicol Pharmacol 167(May):106033; doi: 10.1016/j.yrtph.2026.106033. PMID: 41577161.

Lea IA, Buerger AN, Vincent MJ,…, Choksi NY, Schaefer H, Britt J, Fitch S, Haws L, Borghoff SJ. 2026. Evaluating the potential carcinogenic hazard of diisononyl phthalate in humans via systematic integration of human, animal cancer studies, and mechanistic data. Curr Res Toxicol 10(Apr 30):100295; doi: 10.1016/j.crtox.2026.100295.

Mahony C, Bartlett A, Fitzpatrick S, Galli C, Hunt P, Inselman A, Jimenez J,…, Rogers J, et al. 2026. A screening strategy for identifying the developmental and reproductive toxicity potential of botanicals. 64(1):639-557; doi: 10.1080/13880209.2026.2659421. PMID: 42048162.

Doepker C, Franzen A, Brorby G*, Wikoff D, Thompson C. From alerts to evidence: Advancing the use of in vivo genotoxicity dose-response data for complex mixtures. Poster/Abstract PA3, International Conference on the Science of Botanicals (ICSB), Oxford, MS, April 2026. (*poster only)

Buerger AN, Vincent MJ, Fitch S, Rivera B, Engel N, Zhang J, Rushton EK, Borghoff SJ. 2026. A mechanistic evaluation of the metabolism disrupting potential of methyl tert-butyl ether. Curr Res Toxicol 10(Apr 20):100290; doi: 10.1016/j.crtox.2026.100290. PMID: 42057916.

Massarsky A, Evans VJB, Fung ES, Yang LGL, Rogers KL, Buerger AN, Maier A, Reichard JF. A framework for assessing the safety of degraded pharmaceuticals for long-duration space missions—Part II: Framework application in four case studies. Crit Rev Toxicol; doi: 10.1080/10408444.2026.2633422. Online ahead of print April 16. PMID: 41988975.

Summan M, Doepker CL, Brorby GP. 2026. Safety evaluation of an aqueous root and leaf extract of Ashwagandha (Withania somnifera). Phytother Res; doi: 10.1002/ptr.70314. Online ahead of print April 15. PMID: 41987003.

Moriarty C, Smith M, Hagerty M, Smith S, Garman B, Cherry J, Jacobellis M, et al. PFOS and PFOA alter mitochondrial metabolism in myoblasts. Poster presented at Carolina Society of Environmental Toxicology and Chemistry, North Carolina State University, Raleigh, NC, 2026.

Jacobellis M, Garcia M, Bain L, Pearce J, Hunt K, Baldwin W. Disruption of energy homeostasis by chemical mixtures containing persistent pollutants in HepG2 and C2C12 cells. Platform presentation, Carolina Society of Environmental Toxicology and Chemistry, North Carolina State University, Raleigh, North Carolina, 2026.

Massarsky A, Evans VJB, Fung ES, Yang LGL, Rogers KL, Buerger AN, Maier A, Reichard JF. A framework for assessing the safety of degraded pharmaceuticals that will be required for long-duration space missions—Part I: Framework development. Crit Rev Toxicol; doi: 10.1080/10408444.2025.2533943. Online ahead of print April 9. PMID: 4195218.

Wikoff D, Brown L. Development of an integrated human and environmental health safety assessment framework: Initial findings and progress from a consortium effort. Abstract 1050, Society of Toxicology 65^th Annual Meeting, San Diego, CA, March 2026.

Wikoff D, Fitch S, Eichenbaum G, Ejaz S, Klaren W, Southall M. Need for fit-for-purpose approaches that integrate dose, mechanism, and context of use with key characteristics when evaluating the carcinogenic potential of widely used therapeutics: A case study of acetaminophen. Abstract 4005, Society of Toxicology 65^th Annual Meeting, San Diego, CA, March 2026.

Vincent M, Wheeler M, Schaefer H, Rhoden J, Fitch S, Wikoff D. Quantitative bias assessment to facilitate assessment of (un)certainty in observational data evaluating acetaminophen use and liver cancer. Abstract 4279, Society of Toxicology 65^th Annual Meeting, San Diego, CA, March 2026.